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Abstract
Aims/hypothesis We assessed the real-world effect of flash monitor (FM) usage on HbA1c levels and diabetic ketoacidosis
(DKA) and severe hospitalised hypoglycaemia (SHH) rates among people with type 1 diabetes in Scotland and across
sociodemographic strata within this population.
Methods This study was retrospective, observational and registry based. Using the national diabetes registry, 14,682 individuals
using an FM at any point between 2014 and mid-2020 were identified. Within-person change from baseline in HbA1c following
FM initiation was modelled using linear mixed models accounting for within-person pre-exposure trajectory. DKA and SHH
events were captured through linkage to hospital admission and mortality data. The difference in DKA and SHH rates between
FM-exposed and -unexposed person-time was assessed among users, using generalised linear mixed models with a Poisson
likelihood. In a sensitivity analysis, we tested whether changes in these outcomes were seen in an age-, sex- and baseline HbA1c-
matched sample of non-users over the same time period.
Results Prevalence of ever-FM use was 45.9% by mid-2020, with large variations by age and socioeconomic status: 64.3%
among children aged <13 years vs 32.7% among those aged ≥65 years; and 54.4% vs 36.2% in the least-deprived vs most-
deprived quintile. Overall, the median (IQR) within-person change in HbA1c in the year following FM initiation was −2.5 (−9.0,
2.5) mmol/mol (−0.2 [−0.8, 0.2]%). The change varied widely by pre-usage HbA1c: −15.5 (−31.0, −4.0) mmol/mol (−1.4 [−2.8,
−0.4]%) in those with HbA1c > 84 mmol/mol [9.8%] and 1.0 (−2.0, 5.5) mmol/mol (0.1 [−0.2, 0.5]%) in those with HbA1c <
54 mmol/mol (7.1%); the corresponding estimated fold change (95% CI) was 0.77 (0.76, 0.78) and 1.08 (1.07, 1.09). Significant
reductions in HbA1c were found in all age bands, sexes and socioeconomic strata, and regardless of prior/current pump use,
completion of a diabetes education programme or early FM adoption. Variation between the strata of these factors beyond that
driven by differing HbA1c at baseline was slight. No change in HbA1c in matched non-users was observed in the same time period
(median [IQR] within-person change = 0.5 [−5.0, 5.5] mmol/mol [0.0 (−0.5, 0.5)%]). DKA rates decreased after FM initiation
overall and in all strata apart from the adolescents. Estimated overall reduction in DKA event rates (rate ratio) was 0.59 [95%
credible interval (CrI) 0.53, 0.64]) after FM vs before FM initiation, accounting for pre-exposure trend. Finally, among those at
higher risk for SHH, estimated reduction in event rates was rate ratio 0.25 (95%CrI 0.20, 0.32) after FM vs before FM initiation.
Conclusions/interpretation FM initiation is associated with clinically important reductions in HbA1c and striking reduction in
DKA rate. Increasing uptake among the socioeconomically disadvantaged offers considerable potential for tightening the current
socioeconomic disparities in glycaemia-related outcomes.
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NHS National Health Service
SCI-DC Scottish Care Information - Diabetes
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SHH Severe hospitalised hypoglycaemia
SIMD Scottish Index of Multiple Deprivation
Introduction
In type 1 diabetes, there has been a shift from traditional
methods of self-monitoring of blood glucose using
fingerpricks and glucometers (compliance can be poor with
<50% adherence to guidelines among people with type 1
diabetes in Sweden [1]) to using new technologies that allow
for more frequent measurements with less discomfort. These
new technologies enable real-time or intermittently scanned
continuous glucose monitoring [2]. The latter is known as
flash monitoring, with the only system currently available
for use in the National Health Service (NHS) in the UK
(including Scotland) being Abbott’s Freestyle Libre. Flash
monitors (FMs) have been available in the UK since late
2014 [3]. They became freely available in Scotland from the
NHS in 2018, having been only self-funded previously.
Eligibility for FM use follows a mixture of criteria defined
by each of the Scottish Health boards.
The largest RCT of FMs (N = 328), IMPACT, demon-
strated a significant effect of FM use on hypoglycaemia
without any significant change in HbA1c. However
IMPACT was restricted to adults with good glycaemic
control (HbA1c ≤ 58 mmol/mol [7.5%]) [4], and is there-
fore not representative of the range of current recipients of
this technology from the NHS. Observational studies have
shown reductions in HbA1c, diabetic ketoacidosis (DKA)
and hypoglycaemia with use of FMs [5–14]. Greater
effects on HbA1c have been found in individuals with
high initial HbA1c but, apart from this, study of variation
in effectiveness across different subgroups of recipients
has been limited, particularly for DKA, where there is a
gap in the literature. It is important to determine whether
any groups benefit less from FMs, as this may indicate a
need for measures to improve efficacy.
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In this paper, we aimed to describe the contemporary prev-
alence of FM use among all those with type 1 diabetes in
Scotland and to examine the association of FM initiation with
glycaemic outcomes (HbA1c, DKA and hypoglycaemia)
across the full range of recipients and within age, sex and
socioeconomic groups, as well as by prior glycaemic control,
insulin pump usage and completed diabetes education
programme. We also examined outcomes among the early




We used anonymised data from the Scottish Care Information -
Diabetes Collaboration (SCI-DC) database, a registry with
extensive electronic health records for all those with diabetes
in Scotland. These routinely collected data include start and end
dates for FM use, as well as prescription data. These data are
also linked to hospital admissions data SMR01 from
Information Services Division Scotland andmortality data from
National Records of Scotland (NRS). The database and linkage
procedure have been described in detail elsewhere [15, 16].
Study population
Among all those alive with type 1 diabetes, observable at any
point between 2014 and mid-2020, we included for glycaemic
outcome analyses those who started using an FM between
2014 and 31 October 2019 to limit the number of recipients
with no post-initiation HbA1c by the end of study date. The
type of diabetes was ascertained based on a validated algo-
rithm [15]. FM start and stop dates were assessed from SCI-
DC device dates and from encashed prescription data for Libre
sensors. Individuals contributed person-time from the latest of
either date of diabetes diagnosis or start of observability in the
Scottish diabetes registry, to the earliest of date of death, last
date of observability, first stop-date of FM use or 30
June 2020 (end of study). Glycaemic measures were assessed
up to a maximum of 5 years prior to FM initiation, hence
individual person-time was left-censored 5 years before FM
initiation date. To disentangle the effect of FM initiation from
that of other devices, person-time was right-censored at the
first start date of insulin pump/continuous glucose monitoring
(CGM) device if these started after FM initiation.
Exposure, outcomes and covariates
The exposure of interest was FM usage. Individual person-
time was partitioned into intervals of 1 year centred on the
date of FM initiation [17]. HbA1c records were obtained from
the SCI-DC data. Individuals’ median HbA1c over time slices
was used for analyses. Baseline value was defined as median
over the 2 years prior to FM initiation for continuous covari-
ates, and most severe state over this time window for discrete
covariates.
Baseline HbA1c was categorised to reflect different levels
of glycaemic control (in mmol/mol [%]: <54 [7.1]; ≥54 [7.1]
to ≤63 [7.9]; ≥64 [8.0] to ≤74 [8.9]; ≥75 [9.0] to ≤84 [9.8]; >84
[9.8]). Data on hospitalisations and deaths for DKA and
severe hypoglycaemia from up to 5 years pre-FM initiation
were obtained using the ICD-10 codes (http://apps.who.int/
classifications/icd10/browse/2016/en) detailed in electronic
supplementary material (ESM) Methods, anywhere on the
discharge summary or cause of death.
Area-level deprivation was measured by the Scottish Index
of Multiple Deprivation (SIMD) 2016 definition [18], which
is based on the postcode of residence. SIMD quintiles were
used for analyses, Q1 being the most deprived. Insulin
pump/CGM exposure and completed diabetes education
programme status were ascertained from SCI-DC. Prior pump
usage was defined as any usage of insulin pump preceding the
initiation of FM, regardless of whether usage continued post-
FM. An early adopter was defined as anyone who started FM
before 2018.
Statistical analyses
Comparison of outcomes between users and non-users of FM
may be subject to allocation bias or confounding by indica-
tion. Therefore, our analyses focused on changes within users
over time in outcomes from pre- to post-initiation of FM. All
analyses were conducted using R version 3.6.0–64 bit [19]
and at significance level 0.05. No imputation of missing data
was performed.
HbA1c Absolute within-person change from baseline HbA1c
was described over time, overall and among the groups of
interest listed above. The significance of reductions was
assessed using a one-sided (difference < 0) Wilcoxon
signed-rank test with a Bonferroni correction for multiple
comparisons of various time points vs baseline.
To account for any background trend over time occurring
in HbA1c prior to FM initiation and for repeated measure-
ments within individuals, we used mixed models adjusted
for time, age, diabetes duration at initiation, sex and baseline
HbA1c [20] (see ESM Methods). Specifically, log-
transformed HbA1c was modelled using linear mixed models,
with a random intercept and time slope on the individual, with
categorical FM exposure time as a covariate, implemented in
nlme 3.1-143 [21]. Model estimates represent change in
HbA1c compared with what the levels would have been had
any pre-exposure trend continued (i.e. the counterfactual). To
examine whether the association of FM with HbA1c varied
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across groups of interest, we compared models with and with-
out the FM × group interaction term using likelihood ratio
tests (LRTs). Further, to examine whether any such interac-
tions were explained by variation in baseline HbA1c across
strata, we tested whether interactions remained significant
when models were adjusted for the interaction term FM ×
baseline HbA1c.
DKA and SHH Crude DKA and severe hospitalised
hypoglycaemia (SHH) rates were described in pre- and post-
FM person-time. Due to their discrete and rare nature, DKA
and SHH event rates were modelled using generalised linear
mixed models with a Poisson likelihood and a random inter-
cept on the individual, with FM exposure as a binary time-
varying covariate and adjusting for pre-FM time trend. To
avoid reliance on approximations of intractable integrals,
these models were implemented in a Bayesian Framework
using rstan 2.19.3, with results expressed as rate ratios with
95% credible intervals (CrIs).
Stratified analyses of DKA rates were conducted across the
groups of interest. Due to the sparser nature of SHH events,
we focused on high risk groups for this outcome: those with a
prior history of SHH in the 5 years pre-FM and those with
baseline HbA1c < 54 mmol/mol (7.1%).
Sensitivity analyses To ensure that any changes in outcomes
attributed to FM use were not confounded by the occurrence
of some more general phenomena coinciding with FM intro-
duction, we performed crude sensitivity analyses of changes
over a similar time period in a sample of non-users, matched
1:1 by sex, baseline HbA1c band and age band at FM initiation
date (ESM Methods). Non-users were defined as individuals
who had never used a device by the user’s date of FM initia-
tion and for at least 6 months thereafter. The significance of
differences in HbA1c was assessed using a one-sided
Wilcoxon signed-rank test with a Bonferroni correction for
multiple comparison. Comparisons of event rates were made
using crude rate ratios.
Results
The study sample-size flowchart is shown in ESM Fig. 1.
Prevalence of FM use
The crude prevalence of ever-FM users among those alive
with type 1 diabetes increased rapidly after reimbursement
began, from 3.1% in 2017 to 45.9% (n = 14,682) by mid-
2020. Usage was higher in female vs male individuals and in
younger vs older age bands (Table 1). Quarterly prevalence by
year and age band is detailed in ESM Fig. 2. Prevalence of use
decreased with HbA1c band, was higher among those with vs
without prior pump usage, those with prior SHH history, and
in those from least vs most-deprived areas. These disparities
were present across age bands and sex, although differences
were smaller in younger vs older age bands (63.7% vs 52.8%
in <13 years band; 22.3% vs 43.8% in ≥65 years band).
Baseline characteristics of ever-users of FM
We included for analyses of glycaemic outcomes 12,256 FM
users who started using the device before 31 October 2019.
Their baseline characteristics are described in ESM Table 1
alongside those of matched non-users. The median FM initi-
ation date was 16 November 2018. The median (IQR) post-
FM initiation follow-up time was 1.5 (1.0, 2.0) years. Among





















<54 mmol/mol (<7.1%) 58.6
54–63 mmol/mol (7.1–7.9%) 61.8
64–74 mmol/mol (8.0–8.9%) 56.4
75–84 mmol/mol (9.0–9.8%) 49.7
>84 mmol/mol (>9.8%) 42.3
Ever insulin pump/CGM usage
No 40.3
Yes 74.8
Ever DKA admission in past 5 years
No 45.7
Yes 46.3




the FM users, 23.4% had initiated a pump prior to FM, and
0.5% (n = 60) had stepped down from a CGM; 29.2% had a
record of any completed diabetes education and 7.6% were
early adopters.
Changes in HbA1c
Overall Among all users combined there was a median (IQR)
reduction in HbA1c of −2.5 (−9.0, 2.5) mmol/mol (−0.2 [−0.8,
0.2]%) (n = 10,761; p < 0.01) within the first year post-
exposure and −2.5 (−9.0, 3.5) mmol/mol (−0.2 [−0.8, 0.3]%)
(n = 758; p < 0.01) for ≥2 years of exposure (Table 2). Over
similar time periods, there was no change in HbA1c in the
matched non-users, as illustrated in Fig. 1 (median [IQR]
within-person change = 0.5 [−5.0, 5.5] mmol/mol [0.0
(−0.5, 0.5)%]). Taking into consideration the slight downward
trend occurring in HbA1c among users prior to FM initiation,
modelled estimates revealed a fold change in HbA1c of 0.94
(0.94, 0.95) at 1 year post-initiation and 0.99 (0.98, 1.00) at
≥2 years (ESM Table 2).
Stratified analyses Since approximately half the FM users had
more than 1 year of follow-up post-exposure, results for strat-
ified analyses focus on the year following FM exposure.
Results beyond that time period are given in the tables for
informative purposes. We did not perform analyses stratified
by prior CGM usage due to the low number of prior CGM
users.
By baseline HbA1c Among FM users, change in HbA1c was
strongly dependent on HbA1c at baseline, ranging from a
median (IQR) reduction of −15.5 (−31.0, −4.0) mmol/mol
(−1.4 [−2.8, −0.4]%) during the first year following FM initi-
ation in those with HbA1c > 84 mmol/mol (9.8%) at baseline
to a slight median (IQR) increase of 1.0 (−2.0, 5.5) mmol/mol
(0.1 [−0.2, 0.5]%) in those with HbA1c < 54 mmol/mol
(7.1%) at baseline (Table 2). Taking into consideration trends
occurring in HbA1c among users prior to FM initiation, the
modelled estimates ranged from a fold change (95% CI) of
0.77 (0.76, 0.78) in those with HbA1c > 84 mmol/mol (9.8%)
at baseline to 1.08 (1.07, 1.09) in those with HbA1c <




































































































Fig. 1 Within-person change
from baseline in HbA1c over time
from FM initiation/index date for
users vs matched non-users. Data
are median (IQR). bef., before
FM initiation; aft., after FM
initiation. The two vertical lines






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































By age band FM initiation was associated with a reduction in
HbA1c in all age bands (Fig. 2a), with smaller estimated
changes in the >64 years band. There was significant variation
in HbA1c at initiation by age (ESM Table 3), with HbA1c
being lowest in those aged <13 years and highest in those aged
19–24 years. As expected from this, reductions in HbA1c were
greatest among the 19–24 years age band. Among those aged
13–18 years, the median observed within-person change was
0.0 (−7.0, 7.0) mmol/mol (0.0 [−0.6, 0.6]%) (ESM Table 4).
However, the modelled estimate, accounting for increase
in HbA1c pre-FM exposure, suggested a reduction
compared with the counterfactual, with a 0.95 (95%
CI 0.94, 0.96) fold change (ESM Table 5). Within any
age band, in those with high HbA1c (≥75 mmol/mol
[9.0%]) at FM initiation, clear reductions were observed
in HbA1c. These were most pronounced in children
(<13 years), with a median (IQR) within-person fall of
−30.5 (−50.0, −12.0) mmol/mol (−2.8 [−4.6, −1.1]%)
(ESM Table 6). Allowing for differences in initial
HbA1c, there was evidence of some variation in the fold























































































































































Fig. 2 Estimated fold changes
(95%CI) in HbA1c within the first
year post FM initiation, compared
with pre-exposure levels, adjusted
for pre-exposure trend, baseline
HbA1c, age, sex and diabetes
duration and stratified by age
band at FM initiation (a), sex (b),
SIMD quintile (c), prior pump
usage (d), prior completed
diabetes education programme
status (e) and early adopter status
(f)
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By sex FM initiation was associated with a similar reduction in
HbA1c in men and women respectively (pinteraction = 0.18;
Fig. 2b).
By SIMD FM initiation was associated with a reduction in
HbA1c in all SIMD quintiles. The magnitude of reduction
was similar across quintiles (pinteraction = 0.10; Fig. 2c),
despite those from more-deprived quintiles presenting with
higher baseline HbA1c (ESM Tables 3, 7, 8).
By prior pump usage FM initiation was associated with a
reduction in HbA1c regardless of prior pump use, although
reductions were smaller in prior pump users (Fig. 2d and
ESM Tables 9, 10), as expected from their lower HbA1c at
baseline compared with those with no prior pump use (ESM
Table 3). However, when allowing for differences in
baseline HbA1c, there was still evidence of some varia-
























































































































































































































































FM exposure status Pre-exposure Post-exposure
Fig. 3 Crude DKA event rates (95%CI) in FMusers, after and before FM
initiation, stratified by baseline HbA1c at initiation (a), age at FM initia-
tion (b), sex (c), SIMD quintile (d), prior pump usage (e), prior completed
diabetes education programme status (f) and early adopter status (g). PY,
person-years
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By prior completed diabetes education programme FM initi-
ation was associated with a reduction in HbA1c regardless of
prior education status (Fig. 2e and ESM Tables 11, 12).
Reductions were higher in those without completed education,
while both groups had similar baseline HbA1c (ESM Table 3).
By early adopter status FM initiation was associated with
similar reductions in HbA1c regardless of early FM adoption
(Fig. 2f and ESM Tables 13, 14).
Changes in DKA rates
There were 53,046 person-years observable for DKA/SHH
events before FM initiation and 19,001 afterwards. DKA rates
pre-FM initiation varied considerably across the strata of inter-
est (Fig. 3). Pre-FM rates were higher in those with high base-
line HbA1c, young adults, those from more-deprived areas,
those with no prior pump use, those with no completed diabe-
tes education programme and in the non-early-adopters.
DKA rates significantly decreased overall after FM initia-
tion (estimated rate ratio from the Bayesian models was 0.59
[95% CrI 0.53, 0.64], see Table 3). At the same time, rates
across non-users decreased slightly but to a much lesser
magnitude: crude rate ratio (95% CI) for post- vs pre-index
time 0.90 (0.85, 0.96) vs 0.67 (0.63, 0.72) in users.
Crude DKA rates decreased in pre- vs posts-FM person-
time among all subgroups examined (Fig. 3), apart from the
adolescent group, where an increase was observed (Fig. 3b).
All reductions were significant apart for those with prior pump
use and those with baseline HbA1c 64–74 mmol/mol (8.0–
8.9%) (Fig. 3a,e).
The Bayesian models adjusting for prior trends showed
reductions in all subgroups apart from those with prior pump
use and those with baseline HbA1c 54–63 mmol/mol (7.1–
7.9%), where there was uncertainty around the result (ESM
Fig. 3). Estimated reduction in rates was most marked among
those with baseline HbA1c ≥ 75 mmol/mol (9.0%) and those
withHbA1c < 54mmol/mol (7.1%), though the credible inter-
val was extremely wide in this subgroup due to the low
number of events (ESM Fig. 3a).
Estimated reductions were most substantial in children
(ESM Fig. 3b). Model results also indicated that, accounting
for increase in DKA rate in pre-FM years, FM was associated
with a reduction in DKA rate among adolescents, compared
with the counterfactual. The magnitude of estimated reduction
was higher in male vs female participants (ESM Fig. 3c), in
those from least- vs most-deprived areas (ESM Fig. 3d) and in
those without vs with prior pump use (ESM Fig. 3.e). Model
results also suggested a higher reduction in those without vs
with prior completed diabetes education programme (ESM
Fig. 3f) and early adopters of FM (ESM Fig. 3g), although
CrIs were wide and overlapped.
Changes in SHH rates
SHH rates slightly decreased overall post-FM (Table 3)
Among those with a prior SHH history, the crude event-rate
was significantly lower during FM-exposed person-time.
Bayesian model estimates supported this finding (estimated
rate ratio 0.25 [95% CrI 0.20, 0.32], see Table 3). We did
not have enough statistical power to analyse pre–post differ-
ences among those with starting HbA1c < 54 mmol/mol
(7.1%), who will probably have been prescribed FM due to
recurrent hypoglycaemia. There were only 109 events
observed pre-FM (crude rate 15.4 [12.7, 18.6] per 1000
person-years) and 26 post-FM (crude rate 9.3 [6.1, 13.7] per
1000 person-years).
Discussion
This study showed that prevalence of FM use increased rapid-
ly among individuals with type 1 diabetes in Scotland after
FMs became free of charge but disparities remain across
deprivation levels. FM initiation was associated with a signif-
icant decrease in HbA1c overall among users. HbA1c reduc-
tions were most pronounced in those with high baseline
HbA1c. HbA1c reductions occurred in all SIMD quintiles and
age groups, and regardless of sex, prior pump use, early adopt-
er status or prior completed diabetes education programme.
Table 3 DKA and SHH crude event rates and estimated rate ratio from adjusted Bayesian models
Event Crude rate pre-FMa Crude rate post-FMa Rate ratio (95% CrI)
DKA
Overall 86.8 (84.3, 89.3); 4604; 53,046.1 58.4 (55.0, 62.0); 1110; 19,000.8 0.59 (0.53, 0.64)
With prior DKA history 544.2 (528.6, 560.1); 4604; 8460.2 267.7 (249.3, 287.0); 789; 2947.5 0.44 (0.40, 0.49)
SHH
Overall 19.2 (18.1, 20.4); 1020; 53,046.1 17.5 (15.6, 19.5); 332; 19,000.8 0.75 (0.62, 0.90)
With prior SHH history 312.2 (293.4, 332.0); 1020; 3266.8 106.7 (88.0, 128.2); 114; 1068.1 0.25 (0.20, 0.32)
a Data are presented as crude rate (95%CI); n events observed; n person-years observed
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FM use was associated with marked reductions in DKA over-
all and generally within all subgroups examined. FM initiation
was also associated with a decrease in SHH among those with
a prior history of SHH.
To our knowledge, our large nationwide study is the first to
examine disparities in the prevalence of FM use in Scotland.
We have confirmed and extended previous glycaemic
outcome findings of small-scale studies in Scotland [6, 22]
by providing generalisable results. We have also augmented
the scope of recent large-scale studies [13, 14] by extensively
exploring variations in HbA1c and DKA outcomes following
the initiation of FM use across sociodemographic strata,
which has not been done before and provides novel informa-
tion crucial to clinical practice.
Efforts made by the Scottish Government, clinical teams,
charities such as Diabetes UK, and people with diabetes to
widen the usage of FMs in Scotland have been successful,
with a tenfold increase in use over the past couple of years.
However, the gap between most- and least-deprived quintiles
persists, although it is smaller than the 4% vs 60% observed in
the most- vs least-deprived quintiles in an Edinburgh diabetes
centre in 2017 prior to NHS funding [3]. This gap highlights
the existence of healthcare inequalities in access to technolo-
gy. The extent to which this relates to user preference or to
failure of the devices being recommended by clinicians is
unclear. Prevalence of use is highest among the paediatric
population but gaps across deprivation levels exist even in this
group.
Our overall findings on HbA1c reductions are in keeping
with previous findings such as those from a single-centre
Edinburgh study (−4 mmol/mol [−0.4%]) [22], meta-
analyses performed on FM and HbA1c, mean −4.5 mmol/
mol [−0.4%] in uncontrolled studies [7], and a registry-study
from the Netherlands (mean −3.3 mmol/mol [−0.3%]) [11].
Less than half of the FM users were followed-up for more than
1 year post-initiation, therefore more longitudinal follow-up is
needed to establish the long-term persistence of the improve-
ments in HbA1c.
Only a few studies have looked at FM use and DKA so far.
Our findings regarding DKA overall are in keeping with those
of other nationwide studies regarding DKA hospitalisation
rates [9, 14]. In a French nationwide database, Roussel et al.
[14] reported that DKA hospitalisation rates fell by 56.2% in
the year after vs before FM initiation. This reduction is bene-
ficial in terms of individuals’ wellbeing and reductions in
healthcare costs, as DKA is expensive to treat [23].
Stratified analyses of DKA rates following FM initiation
are lacking in the literature. The variations in HbA1c changes
from baseline across starting HbA1c were in keeping with
those reported in previous studies: slight increase among those
with optimally controlled baseline HbA1c [6, 24]; and substan-
tial decrease among those with high baseline HbA1c [6, 7, 10,
13, 22]. We also found that reductions in DKA rates post- vs
pre-FM were most marked in those with high baseline HbA1c.
These improvements are extremely promising and likely to
translate into a reduction in healthcare costs as those with high
HbA1c levels are most at risk of complications [25].
We found that FM use was associated with improvements in
HbA1c in all SIMD quintiles, showing that this technology bene-
fits all, including those from more-deprived areas. Tsur et al. [9]
also reported significant improvements in HbA1c among those
with lower socioeconomic status. Although the magnitude of
reduction in DKA rates was higher among those from least-
deprived areas, there were marked improvements in all SIMD
quintiles. Unequal distribution of, or access to, this technology
may further widen existing inequalities in healthcare, especially
since those from more-deprived areas have historically higher
HbA1c [26] and thus stand to benefit most from FM.
Existing paediatric studies have had small sample sizes [7,
8] with heterogeneous findings. For example, Campbell et al.
[27] reported a significant decrease in HbA1c among children
aged 4–17 years, while Messaaoui et al. [28] reported no
change in HbA1c among their sample of children/young
people aged 4–20 years. In our study, HbA1c reduction
appeared to be smaller among the paediatric group, although
this was expected considering the well-controlled baseline
HbA1c. Conversely, reduction in DKA rates was substantial
in children. Among those with high baseline HbA1c, marked
reductions in HbA1c were observed in all age groups.
Despite minimal observed reduction in HbA1c and
observed increase in crude DKA rate among adolescents,
model results accounting for prior trends suggested improve-
ment in both areas. Longer post-FM follow-up is needed
among adolescents to better understand how or whether FM
use mitigates the usual deterioration in HbA1c among this age
group. It is also important to consider factors other than blood
glucose outcomes when evaluating the benefits of FM in this
group, such as quality of life. Indeed, qualitative studies [29,
30] have suggested such improvements in this demographic.
Al Hayek et al. [31] also found a significant reduction in
diabetes distress in a sample of 187 adolescents. However,
we do not have access to such data and additional work needs
to be done to examine whether FM usage among adolescents
could be improved further.
The smaller reductions observed among those with prior
pump use was consistent with their lower baseline HbA1c, and
was in keeping with other findings [9]. Individuals using insu-
lin pumps in Scotland attend a structured education
programme prior to pump initiation and receive substantial
input from diabetes support services. Therefore, gains in terms
of HbA1c are expected to be marginal in this group. The non-
significant decrease in DKA is likely due to significant
improvements already occurring following pump initiation
[32]. Improvements in this group are expected in terms of
quality of life or hypoglycaemia but we did not possess data
to assess this.
Diabetologia
DKA and HbA1c improved regardless of completion of a
diabetes education programme but individual education levels
were not available to assess their influence on outcomes.
Interestingly, disparities in DKA rates between strata
before FM initiation generally persisted even after the post-
FM reductions. This highlights the need to better understand
drivers of elevated DKA rates. Indeed, O’Reilly et al. [33]
showed that factors beyond structured education, use of pump
and HbA1c likely contributed to elevated rates among most-
deprived quintiles.
Our findings suggest that FM use is associated with a reduc-
tion in SHH among those at risk of this complication. Results on
FM usage and hypoglycaemia in the literature vary. The
IMPACT study [4] showed a reduction in hypoglycaemia in
thosewith well-controlledHbA1c. Observational studies reported
a significant decrease in severe hypoglycaemia [5, 9, 13, 14],
while Campbell et al. [27] found time in hypoglycaemia to be
unaffected in their paediatric sample. Differences in results are
likely due to a combination of differing hypoglycaemia defini-
tions and cohort characteristics/behaviour. It is nonetheless
important to understand whether there is any over-adjustment
of insulin dose following readings of FM data.
Strengths and limitations
Our study is one of the largest contemporary real-world-setting
studies examining the association of FM initiation with
glycaemic outcomes combining data from nationwide electronic
health records with extensive subgroup analyses, in particular
filling a gap in the literature with regards to FM use and DKA.
Using data from all individuals with type 1 diabetes in Scotland,
wewere able to capture current disparities in usage in the country
and had enough power to explore a large number of
sociodemographic group-specific outcomes.
For comparison, a recent large-scale UK-based voluntary
audit [10] possessed post-FM follow-up HbA1c measures for
only one-third of the users included (3182 out of 9968), while
recent national Swedish and French studies [13, 14] did not
examine variations across sociodemographic groups.
We were limited in our analyses of hypoglycaemia by only
being able to analyse hospital admissions, which represent a
tiny fraction of hypoglycaemic events [34]. We did not have
access to granular glucose data from the Libre devices; this
would have allowed better understanding of glycaemic vari-
ability and analysis of hypoglycaemia with more precision.
Our study suffers from the usual biases linked to observational
studies, such as unmeasured confounding or measurement
error. Since this study was observational, observed changes
were not attributable to FM use in the clear-cut manner of an
RCT. However, timing of changes and crude comparisons to
non-users support the findings in relation to FM initiation.
Since the end of our study, newer FM models such as the
Libre 2 have become available (since January 2021). Our
findings pertaining to marked improvements even with first-
generation Libre devices herald positive outcomes with more
updated Libre versions.
Due to the criteria of eligibility for FM use, our results
might not be generalisable to all those with type 1 diabetes.
These criteria are less restrictive than eligibility to insulin
pumps, which were also found to be associated with improved
glycaemic outcomes among people with type 1 diabetes in
Scotland [32]. It is nonetheless crucial to understand the deter-
minants of good response to FMs to optimise a more wide-
spread roll-out. For example, Riveline et al. [35], among
others, showed that scanning frequency is associated with
better glycaemic outcomes; however, we did not have access
to such data.
Conclusions
Flash glucose monitoring use in Scotland has been associated
with clinically important improvements in HbA1c, especially
in individuals with high baseline HbA1c who have the most to
gain in reducing the risk of diabetes complications.
Historically, reducing rates of DKA has proven to be an
extremely difficult task and uptake of effective interventions
(such as structured education) has often been relatively low.
The striking reduction in DKA across the sociodemographic
spectrum following FM use is of major clinical importance.
More research is needed to better understand how to increase
the uptake of FM use and the drivers and features of its effect
in order to tighten the existing socioeconomic gaps. Results
will need to be updated when longer-term follow-up is avail-
able and to keep pace with newer technologies and systems
such as newer Libre models, DIY closed-loop systems or offi-
cially licensed hybrid-loop systems.
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